TherapeuticsMD Inc (TXMD)

6.41
AMEX : Health Care
Prev Close 6.26
Day Low/High 6.18 / 6.43
52 Wk Low/High 5.18 / 11.26
Avg Volume 1.27M
Exchange AMEX
Shares Outstanding 196.49M
Market Cap 1.23B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Picking Up More TherapeuticsMD

The company is less than 48 hours removed from the latest milestone in its product pipeline, so we'll buy on weakness.

TherapeuticsMD Gains FDA Application Nod

The application is for Yuvvexy, a biosimilar hormone treatment for vulvar and vaginal atrophy.

TherapeuticsMD Announces FDA Acceptance Of New Drug Application (NDA) And Prescription Drug User Fee Act (PDUFA) Date For Yuvvexy™ (TX-004HR)

TherapeuticsMD Announces FDA Acceptance Of New Drug Application (NDA) And Prescription Drug User Fee Act (PDUFA) Date For Yuvvexy™ (TX-004HR)

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the acceptance of the NDA for Yuvvexy, the conditionally-approved trade name for TX-004HR, by the U.

Stocks Under $10 Weekly Summary

We continue to screen new names amid a week of volatility in the broader market.

Novavax's Steep Decline Underlines Small-Cap Biotech Risk

But we remain committed to our position in TherapeuticsMD.

Stocks Under $10 Weekly Summary

We added one new name to the Bullpen during a holiday-shortened week that ended with the worst daily decline since late June.

Stocks Under $10 Portfolio: Not Resting on Our Laurels

Stocks Under $10 Portfolio: Not Resting on Our Laurels

The portfolio has outperformed the Russell 2000 index by more than 400 basis points, year to date.

Stocks Under $10 Weekly Summary

We added to two portfolio positions this week and also used market strength to book some profits.

Buying More TherapeuticsMD

We'll put some cash from earlier sales back to work, adding more TXMD on weakness.

Stocks Under $10 Weekly Summary

In a largely quiet week for the market, we exited one position and trimmed 2 others, booking profits in each case.

Stocks Under $10 Weekly Roundup

We used market volatility to add a new position this week and add take profits in another holding.

Stocks Under $10 Weekly Roundup

We used market volatility this week to close one position and add to two others.

Buying More TherapeuticsMD

The maker of women's health products could receive FDA approval for two late-stage products in the next 18 months.

Stocks Under $10 Weekly Summary

It was a busy time of earnings reports for the model portfolio, as the market rose for the sixth straight week.

Ballantyne and TherapeuticsMD Rise Off 2Q Results

We maintain our Two rating and price target on each stock.

TherapeuticsMD Announces Second Quarter 2016 Financial Results

TherapeuticsMD Announces Second Quarter 2016 Financial Results

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its second quarter financial results for the quarter ended June 30, 2016.

Four Portfolio Names to Report Results

Ballantyne Strong, Builders FirstSource, Kratos Defense & Security and Therapeutics MD are on tap for after-hours releases.

TherapeuticsMD To Host Second Quarter Financial Results

TherapeuticsMD To Host Second Quarter Financial Results

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss second quarter financial and business results on...

TherapeuticsMD Announces New Drug Application Submission For Yuvvexy™ (TX-004HR)

TherapeuticsMD Announces New Drug Application Submission For Yuvvexy™ (TX-004HR)

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, announced today that it has submitted its New Drug Application (NDA) for Yuvvexy with the U.

TherapeuticsMD Announces Filing Timeline For Yuvvexy (TX-004HR) New Drug Application

TherapeuticsMD Announces Filing Timeline For Yuvvexy (TX-004HR) New Drug Application

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, announced today that it expects that the New Drug Application (NDA) for Yuvvexy, the conditionally approved trade name for the Company's...

Stocks Under $10 Weekly Roundup

With market weakness expected to continue to linger, our model portfolio considers it a potentially good time to buy.

Stocks Under $10 Weekly Roundup

We trimmed two positions in the model portfolio this week amid overall market strength.

TherapeuticsMD Announces New Innovation In Compliance Packaging For Prenatal Vitamins

TherapeuticsMD Announces New Innovation In Compliance Packaging For Prenatal Vitamins

TherapeuticsMD, Inc. (NYSE MKT:TXMD) an innovative women's healthcare company and parent company of vitaMedMD ®, LLC ("vitaMedMD") and BocaGreenMD ®, Inc.

Stocks Under $10 Weekly Roundup

With the probability of an interest rate hike at the June FOMC of just 4% and also lingering uncertainty about rising interest rates over coming weeks and months, we remain comfortable with the model portfolio.

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will participate in two upcoming investor conferences.

Stocks Under $10 Weekly Roundup

U.S. shares advanced for the week, but we did not make any trades in our model portfolio. Next week, however, a plethora of economic data will be released.

Stocks Under $10 Weekly Roundup

U.S. stocks are approaching oversold levels for the first time in over a month, leaving us comfortable with an above-average 25% cash position in our model portfolio as we search for new names to add.

TherapeuticsMD Presents Poster At ACOG 2016 With Additional Secondary Endpoint Data From Phase 3 Rejoice Trial

TherapeuticsMD Presents Poster At ACOG 2016 With Additional Secondary Endpoint Data From Phase 3 Rejoice Trial

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, presented additional secondary endpoint results from the pivotal phase 3 Rejoice Trial for its TX-004HR product candidate at the American...